Health Canada approves Arcutis' Zoryve for Plaque Psoriasis
Health Canada has granted approval to Arcutis’ Zoryve (roflumilast) cream 0.3% to treat people aged 12 years and above with Plaque Psoriasis.
Hydroarq Technology News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Hydroarq Technology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Hydroarq Technology Today - Breaking & Trending Today
Arcutis Launches ZORYVE (Roflumilast) Cream 0.3% in the United States for Treatment of Plaque Psoriasis in Individuals Age 12 and Older
10.08.2022 - Next-generation topical PDE4 inhibitor for adults and adolescents with plaque psoriasis now available in pharmacies nationwideEffective, safe, and very well-tolerated steroid-free cream that rapidly clear plaques and reduces itch Arcutis committed ... Seite 1
Source: wallstreet-online.de
FDA Approves Arcutis' ZORYVE Cream For Treatment Of Plaque Psoriasis In Patients 12 Years And Older
(RTTNews) - Arcutis Biotherapeutics, Inc. (ARQT), an early commercial-stage biopharmaceutical company, Friday announced that the U.S. Food and Dru...
Source: businessinsider.com